EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy

Atsushi Ogawa iD, Hiroshi Kawamoto, Junichi Hara iD, Atsushi Kikuta iD, Chitose Ogawa, Hiroaki Hiraga iD, Kenichi Yoshimura, Kazunari Miyairi, Reiko Omori, Tokihiro Ro, Yuna Kamei, Toshimi Kimura

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04664-6 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Atsushi Ogawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho Chuo-ku, Niigata, 951-8566, Japan. atsushi@niigata-cc.jp. Hauptthemen laut MEDLINE: Methotrexate, gamma-Glutamyl Hydrolase, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Medical Association, Ohara Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

High-dose methotrexate therapy (HD-MTX) is a standard treatment for various malignant tumors, but approximately 1–10% of patients experience delayed MTX elimination (DME) that can induce organ damage. Glucarpidase can hydrolyze MTX and thereby lower the level of active MTX in the blood. A multicenter, open-label, phase II investigator-initiated trial (CPG2-PII study) was conducted to evaluate glucarpidase rescue therapy in Japanese patients who showed DME after HD-MTX treatment. To confirm the robustness of this therapy, further corporate-sponsored clinical trial (OP-07-001 study) was conducted.

Methods

The primary endpoint in the CPG2-PII study was to evaluate the proportion of patients of the percentage clinical important reduction (CIR) as an indicator of MTX concentration, which can be managed with leucovorin and supportive care. The primary endpoint of the OP-07-001 study was to evaluate the decreasing rate of plasma MTX concentration at 20 min after glucarpidase administration from the baseline for four patients. Glucarpidase was administered at a dose of 50 U/kg for 15 and 4 patients, respectively in the two studies, and safety was analyzed for each of them.

Results

The rate of CIR was 76.9% (95% confidence interval, 46.2–95.0%) in the CPG2-PII study. The median reduction rate of plasma MTX was 98.83% in the OP-07-001 study. Hypersensitivity, blood bilirubin increased, and headache for each patient were the only study drug-related events.

Conclusion

Glucarpidase showed an effect of reducing plasma MTX concentration in Japanese patients with DME as that observed in a previous US study, confirming its favorable safety and tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methotrexategamma-Glutamyl HydrolaseAntimetabolites, AntineoplasticHumansFemaleMaleMiddle AgedAgedAdultNeoplasmsRecombinant ProteinsDose-Response Relationship, Drug

Stichwörter der Autor:innen

CPG2Clinical studyGlucarpidaseHD-MTXJapan

Substanzen

Methotrexategamma-Glutamyl HydrolaseglucarpidaseAntimetabolites, AntineoplasticRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho Chuo-ku, Niigata, 951-8566, Japan. atsushi@niigata-cc.jp.
  • Department of Pediatric and Allergy, Fujimi Clinic, Tokyo, Japan.
  • Department of Pediatrics Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
  • Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
  • Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Musculoskeletal Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan.

ORCID-Profile: Atsushi Ogawa, Junichi Hara, Atsushi Kikuta, Hiroaki Hiraga

Förderung

  • Japan Medical Association
  • Ohara Pharmaceutical Co., Ltd.

Zitieren

APA

Ogawa, A., Kawamoto, H., Hara, J., Kikuta, A., Ogawa, C., Hiraga, H., Yoshimura, K., Miyairi, K., Omori, R., Ro, T., Kamei, Y., & Kimura, T. (2024). Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04664-6

Vancouver

Ogawa A, Kawamoto H, Hara J, Kikuta A, Ogawa C, Hiraga H, et al. Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04664-6

BibTeX
@article{Ogawa2024,
  author = {Ogawa, Atsushi and Kawamoto, Hiroshi and Hara, Junichi and Kikuta, Atsushi and Ogawa, Chitose and Hiraga, Hiroaki and Yoshimura, Kenichi and Miyairi, Kazunari and Omori, Reiko and Ro, Tokihiro and Kamei, Yuna and Kimura, Toshimi},
  title = {Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04664-6}
}
Kostenlos starten →